Indeed, we observed that a treatment combining P36 with the ALK-specific inhibitor crizotinib resulted in additive cytotoxicity in ALK-bearing tumor cells in vitro in two cell models, ALCL, and neuroblastoma [89]. Here, ALK is linked to neoplasm.